OBJECTIVE: Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), can occur in patients receiving natalizumab for multiple sclerosis (MS). JCV detection by quantitative polymerase chain reaction (qPCR) in cerebrospinal fluid (CSF), or brain biopsy, is required for probable or definite diagnosis of PML. However, in some patients only low levels of JCV DNA (<100 copies/ml) are present in CSF, making the diagnosis challenging. Our objective was to assess the complementary value of a CSF JCV antibody index (AIJCV ) in the diagnosis of natalizumab-associated PML. METHODS: AIJCV was assessed in 37 cases of natalizumab-associated PML and 89 MS-patients treated with natalizumab without PML. Sera and CSF were tested in a capture enzyme-linked immunosorbent assay, using JCV-VP1 fused to glutathione S-transferase as antigen. Albumin levels and total immunoglobulin G concentration were determined by immunonephelometry, and the AIJCV was calculated as published. RESULTS: Twenty-six of 37 (70%) patients with natalizumab-associated PML exhibited an AIJCV > 1.5, whereas this was seen in none of the controls (p < 0.0001). At time of the first positive qPCR for JCV DNA, 11 of 20 (55%) patients with natalizumab-associated PML had an AIJCV > 1.5. JCV DNA levels of <100 copies/ml were seen in 14 (70%) of these 20 patients, of whom 8 (57%) demonstrated an AIJCV > 1.5. INTERPRETATION: Determination of the AIJCV could be an added tool in the diagnostic workup for PML and should be included in the case definition of natalizumab-associated PML.
OBJECTIVE: Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), can occur in patients receiving natalizumab for multiple sclerosis (MS). JCV detection by quantitative polymerase chain reaction (qPCR) in cerebrospinal fluid (CSF), or brain biopsy, is required for probable or definite diagnosis of PML. However, in some patients only low levels of JCV DNA (<100 copies/ml) are present in CSF, making the diagnosis challenging. Our objective was to assess the complementary value of a CSF JCV antibody index (AIJCV ) in the diagnosis of natalizumab-associated PML. METHODS: AIJCV was assessed in 37 cases of natalizumab-associated PML and 89 MS-patients treated with natalizumab without PML. Sera and CSF were tested in a capture enzyme-linked immunosorbent assay, using JCV-VP1 fused to glutathione S-transferase as antigen. Albumin levels and total immunoglobulin G concentration were determined by immunonephelometry, and the AIJCV was calculated as published. RESULTS: Twenty-six of 37 (70%) patients with natalizumab-associated PML exhibited an AIJCV > 1.5, whereas this was seen in none of the controls (p < 0.0001). At time of the first positive qPCR for JCV DNA, 11 of 20 (55%) patients with natalizumab-associated PML had an AIJCV > 1.5. JCV DNA levels of <100 copies/ml were seen in 14 (70%) of these 20 patients, of whom 8 (57%) demonstrated an AIJCV > 1.5. INTERPRETATION: Determination of the AIJCV could be an added tool in the diagnostic workup for PML and should be included in the case definition of natalizumab-associated PML.
Authors: E Iacobaeus; C Ryschkewitsch; M Gravell; M Khademi; E Wallstrom; T Olsson; L Brundin; Eo Major Journal: Mult Scler Date: 2008-09-19 Impact factor: 6.312
Authors: David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath Journal: Lancet Neurol Date: 2010-04 Impact factor: 44.182
Authors: T Weber; C Trebst; S Frye; P Cinque; L Vago; C J Sindic; W J Schulz-Schaeffer; H A Kretzschmar; W Enzensberger; G Hunsmann; W Lüke Journal: J Infect Dis Date: 1997-07 Impact factor: 5.226
Authors: C J Sindic; C Trebst; M P Van Antwerpen; S Frye; W Enzensberger; G Hunsmann; W Lüke; T Weber Journal: J Neuroimmunol Date: 1997-06 Impact factor: 3.478
Authors: B Giudici; B Vaz; S Bossolasco; S Casari; A M Brambilla; W Lüke; A Lazzarin; T Weber; P Cinque Journal: Clin Infect Dis Date: 2000-01 Impact factor: 9.079
Authors: Samantha Jilek; Emilie Jaquiéry; Hans H Hirsch; Andreas Lysandropoulos; Mathieu Canales; Laurence Guignard; Myriam Schluep; Giuseppe Pantaleo; Renaud A Du Pasquier Journal: Lancet Neurol Date: 2010-01-29 Impact factor: 44.182
Authors: Caroline Ryschkewitsch; Peter Jensen; Jean Hou; Gary Fahle; Steven Fischer; Eugene O Major Journal: J Virol Methods Date: 2004-11 Impact factor: 2.014
Authors: Yiping Chen; Evelyn Bord; Troy Tompkins; Janice Miller; Chen S Tan; R Philip Kinkel; Marion C Stein; Raphael P Viscidi; Long H Ngo; Igor J Koralnik Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin Journal: Sci Transl Med Date: 2015-09-23 Impact factor: 17.956
Authors: L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl Journal: Nervenarzt Date: 2016-06 Impact factor: 1.214
Authors: Martijn T Wijburg; Iris Kleerekooper; Birgit I Lissenberg-Witte; Marlieke de Vos; Clemens Warnke; Bernard M J Uitdehaag; Frederik Barkhof; Joep Killestein; Mike P Wattjes Journal: JAMA Neurol Date: 2018-07-01 Impact factor: 18.302
Authors: Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik Journal: Ann Neurol Date: 2015-07-31 Impact factor: 10.422